ENEX Energy Corp. (PSE:ENEX)

Ligand Pharmaceuticals Income Statement

Financials in millions PHP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cost of Revenue	0.17	0.17	0.19	0.1	-	0.01
Gross Profit	-0.17	-0.17	-0.19	-0.1	-	-0.01
Selling, General & Admin	12.24	11.28	14.47	24.84	12.17	12.52
Other Operating Expenses	1.34	1.42	0.61	4.76	4.26	0.26
Operating Expenses	13.68	12.84	15.23	29.75	16.6	12.95
Operating Income	-13.85	-13	-15.43	-29.86	-16.6	-12.96
Interest Expense	-3.2	-6.72	-9.96	-5.33	-	-
Interest & Investment Income	0.45	0.33	0.01	0.01	0.02	0.06
Earnings From Equity Investments	-10.16	-14.55	-30.64	-38.77	-	-
Currency Exchange Gain (Loss)	0.11	0.25	-0.1	1.11	0.59	-0.63
Other Non Operating Income (Expenses)	2.81	1.08	4.5	-0.91	-0.24	-0.64
EBT Excluding Unusual Items	-23.83	-32.61	-51.62	-73.74	-16.23	-14.16
Asset Writedown	-	-	-	-	-23.96	-
Pretax Income	-23.83	-32.61	-51.62	-73.74	-40.19	-14.16
Income Tax Expense	0.06	0.09	0	-	-	-0.01
Earnings From Continuing Operations	-23.9	-32.7	-51.62	-73.74	-40.19	-14.15
Minority Interest in Earnings	0.64	0.62	-0	-0.19	2.41	2.38
Net Income	-23.26	-32.08	-51.62	-73.94	-37.78	-11.77
Net Income to Common	-23.26	-32.08	-51.62	-73.94	-37.78	-11.77
Shares Outstanding (Basic)	250	250	250	250	250	250
Shares Outstanding (Diluted)	250	250	250	250	250	250
EPS (Basic)	-0.09	-0.13	-0.21	-0.30	-0.15	-0.05
EPS (Diluted)	-0.09	-0.13	-0.21	-0.30	-0.15	-0.05
Free Cash Flow	-30.98	-26.12	-17.89	-22.03	-16.29	-19.83
Free Cash Flow Per Share	-0.12	-0.10	-0.07	-0.09	-0.07	-0.08
EBITDA	-13.72	-12.87	-15.27	-29.7	-16.43	-12.79
D&A For EBITDA	0.13	0.13	0.16	0.16	0.17	0.17
EBIT	-13.85	-13	-15.43	-29.86	-16.6	-12.96
Advertising Expenses	-	1.26	0.28	0.77	0.01	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.